Literature DB >> 10520628

A stimulating new target for cancer immunotherapy.

J Schultze1, P Johnson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10520628     DOI： 10.1016/S0140-6736(99)90130-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.

Authors:  Sean K Kelley; Thomas Gelzleichter; Dong Xie; Wyne P Lee; Walter C Darbonne; Ferhan Qureshi; Kim Kissler; Ezogelin Oflazoglu; Iqbal S Grewal
Journal:  Br J Pharmacol       Date:  2006-07-10       Impact factor: 8.739

2.  Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Cristina M Lu; Elaine B Brooks; Richard E Fichtl; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

Review 3.  Novel approaches to the immunotherapy of B-cell malignancies: An update.

Authors:  Renier J Brentjens
Journal:  Curr Hematol Malig Rep       Date:  2006-12       Impact factor: 4.213

4.  Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma.

Authors:  Ihab Abd-Elrahman; Taher Nassar; Noha Khairi; Riki Perlman; Simon Benita; Dina Ben Yehuda
Journal:  Oncogene       Date:  2020-10-30       Impact factor: 9.867

Review 5.  Novel approaches to immunotherapy for B-cell malignancies.

Authors:  Renier J Brentjens
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.945
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.